Updated:
Veristat
Veristat is a contract research organization and consultancy founded in 1994 in Southborough, Massachusetts. The company provides services in clinical trial...
Veristat
Veristat is a contract research organization and consultancy founded in 1994 in Southborough, Massachusetts. The company provides services in clinical trial planning and conduct, regulatory affairs, and strategic consulting. It supports the development of biologics, drugs, and medical devices in therapeutic areas such as oncology, neurology, endocrinology, immunology, and infectious diseases.
General information
Firm type
Asset Manager
Year founded
1994
Location
Region
North America
Country
United States
City
Southborough
Corporate office
Southborough, MA, United States
Sector focus
Frequently asked questions
Is Veristat a family office or an investment vehicle?
Veristat is neither a family office nor an investment vehicle. It is a clinical research organization (CRO) that earns fee-for-service revenue by managing clinical trials and providing regulatory consulting for biopharmaceutical companies. The firm does not take equity in its clients or invest proprietary capital on their behalf.
What differentiates Veristat from the largest CROs like IQVIA or Parexel?
Veristat competes in the mid-tier CRO space, deliberately staying below the enterprise scale of IQVIA or Parexel. Its pitch to sponsors emphasizes continuity of project teams, a higher ratio of senior staff per engagement, and an in-house strategic regulatory-consulting unit that designs the approval pathway alongside trial execution — an integrated model that large CROs often split across separate business units.
What therapeutic areas does Veristat have the deepest regulatory success in?
Based on the firm's published case studies and conference presentations, oncology and rare disease represent the heaviest concentration of its regulatory-submission support. Veristat has also publicly described programs in neurology, infectious disease, and medical-device regulation, particularly in markets transitioning under EU MDR.
Does Veristat participate in co-investments or clinical-trial financing?
No, Veristat is a pure service provider. It does not operate a venture arm, a co-investment vehicle, or a clinical-trial financing fund. Sponsors pay Veristat on a contractual basis for trial management, data services, and regulatory consulting; Veristat does not carry asset risk on its books.
Where does Veristat maintain operational offices beyond its Massachusetts headquarters?
Veristat has publicly listed offices in several European countries plus Israel, as well as a presence in East Asia to support regional trial monitoring. The firm does not disclose a full real-time office roster, but its published recruitment activity confirms ongoing operations in at least Germany and the United Kingdom.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: